Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
Ashkenazi-Jewish
BRCA
cultural
denomination
population-based
religious
Journal
BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528
Titre abrégé: BJOG
Pays: England
ID NLM: 100935741
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
11
09
2021
received:
18
03
2021
accepted:
30
09
2021
pubmed:
11
11
2021
medline:
23
4
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
To evaluate the association of Jewish cultural and religious identity and denominational affiliation with interest in, intention to undertake and uptake of population-based BRCA (Breast Cancer Gene)-testing. Cohort-study set within recruitment to GCaPPS-trial (ISRCTN73338115). London Ashkenazi-Jewish (AJ) population. AJ men and women, >18 years. Participants were self-referred, and attended recruitment clinics (clusters) for pre-test counselling. Subsequently consenting individuals underwent BRCA testing. Participants self-identified to one Jewish denomination: Conservative/Liberal/Reform/Traditional/Orthodox/Unaffiliated. Validated scales measured Jewish Cultural-Identity (JI) and Jewish Religious-identity (JR). Four-item Likert-scales analysed initial 'interest' and 'intention to test' pre-counselling. Item-Response-Theory and graded-response models, modelled responses to JI and JR scales. Ordered/multinomial logistic regression modelling evaluated association of JI-scale, JR-scale and Jewish Denominational affiliation on interest, intention and uptake of BRCA testing. Interest, intention, uptake of BRCA testing. In all, 935 AJ women/men of mean age = 53.8 (S.D = 15.02) years, received pre-test education and counselling through 256 recruitment clinic clusters (median cluster size = 3). Denominational affiliations included Conservative/Masorti = 91 (10.2%); Liberal = 82 (9.2%), Reform = 135 (15.1%), Traditional = 212 (23.7%), Orthodox = 239 (26.7%); and Unaffiliated/Non-practising = 135 (15.1%). Overall BRCA testing uptake was 88%. Pre-counselling, 96% expressed interest and 60% intention to test. JI and JR scores were highest for Orthodox, followed by Conservative/Masorti, Traditional, Reform, Liberal and Unaffiliated Jewish denominations. Regression modelling showed no significant association between overall Jewish Cultural or Religious Identity with either interest, intention or uptake of BRCA testing. Interest, intention and uptake of BRCA testing was not significantly associated with denominational affiliation. Jewish religious/cultural identity and denominational affiliation do not appear to influence interest, intention or uptake of population-based BRCA testing. BRCA testing was robust across all Jewish denominations. Jewish cultural/religious factors do not affect BRCA testing, with robust uptake seen across all denominational affiliations.
Identifiants
pubmed: 34758513
doi: 10.1111/1471-0528.16994
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
959-968Subventions
Organisme : The Eve Appeal
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Manchanda R, Burnell M, Gaba F, Desai R, Wardle J, Gessler S, et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes. BJOG 2020;127:364-75.
Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Netw Open 2018;1:e182140.
Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population frequency of germline BRCA1/2 mutations. J Clin Oncol 2016;34:4183-5.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:2402-16.
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296:185-92.
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-62.
Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381:1827-34.
Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 2015;107:379.
Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 2014;111:14205-10.
Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, et al. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study. BJOG 2019;126:784-94.
Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, et al. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J Med Genet 2016;53:472-80.
Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing. J Natl Cancer Inst 2015;107:380.
Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. Am J Obstet Gynecol 2017;217:578.e1-2.
Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E. Population screening for inherited predisposition to breast and ovarian cancer. Annu Rev Genomics Hum Genet 2020;21:373-412.
Amyot RP, Sigelman L. Jews without Judaism? Assimilation and Jewish identity in the United States. Soc Sci Q 1996;77:13.
Bowen DJ, Singal R, Eng E, Crystal S, Burke W. Jewish identity and intentions to obtain breast cancer screening. Cultur Divers Ethnic Minor Psychol 2003;9:79-87.
Genetic counselling. Am J Hum Genet 1975;27:240-2.
Resta R, Biesecker BB, Bennett RL, Blum S, Hahn SE, Strecker MN, et al. A new definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force report. J Genet Couns 2006;15:77-83.
NCI. Genetic Counselling. Cancer Genetics Overview (PDQ). Bethesda, MD: NCI; 2013 [http://www.cancer.gov/cancertopics/pdq/genetics/overview/healthprofessional/page2]. Accessed 31 July 2013.
Phinney J. The multigroup ethnic identity measure: a new scale for use with diverse groups. J Adolesc Res 1992;7:156-76.
Prochaska JO, Velicer WF, Rossi JS, Goldstein MG, Marcus BH, Rakowski W, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994;13:39-46.
Sanderson SC, Wardle J, Jarvis MJ, Humphries SE. Public interest in genetic testing for susceptibility to heart disease and cancer: a population-based survey in the UK. Prev Med 2004;39:458-64.
Bosompra K, Flynn BS, Ashikaga T, Rairikar CJ, Worden JK, Solomon LJ. Likelihood of undergoing genetic testing for cancer risk: a population-based study. Prev Med 2000;30:155-66.
Bunn JY, Bosompra K, Ashikaga T, Flynn BS, Worden JK. Factors influencing intention to obtain a genetic test for colon cancer risk: a population-based study. Prev Med 2002;34:567-77.
Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997;89:148-57.
Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women. Cancer 2001;92:932-40.
JPR. Jews the United Kingdom in 2013: Preliminary Findings from the National Jewish Community Survey. London: Institute for Jewish Policy Research; 2014.
JPR. JPR/Report. Key Trends in the British Jewish Community. London: Institute for Jewish Policy Research; 2011.
Pew Research Center. A Portrait of Jewish Americans. Findings from a Pew Research Center Survey of US Jews. Washington, DC: Pew Research Center; 2013.
Hann KEJ, Freeman M, Fraser L, Waller J, Sanderson SC, Rahman B, et al. Awareness, knowledge, perceptions, and attitudes towards genetic testing for cancer risk among ethnic minority groups: a systematic review. BMC Public Health 2017;17:503.
Rosner F, Bleich J. Jewish Bioethics. Brooklyn, New York: KTAV Publishing; 2000.
Schwartz MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol 2014;32:618-26.
Forde C, Brunstrom K, Woodward E, Bowers N, Pereira M, Wallace AJ, et al. Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent. J Med Genet 2021;58:74-8.
Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, et al. Understanding factors associated with uptake of BRCA1/2 genetic testing among orthodox Jewish women in the USA using a mixed-methods approach. Public Health Genomics 2018;21:186-96.